These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 33323403)

  • 1. Genome-wide Copy-number Alterations in Circulating Tumor DNA as a Novel Biomarker for Patients with High-grade Serous Ovarian Cancer.
    Paracchini L; Beltrame L; Grassi T; Inglesi A; Fruscio R; Landoni F; Ippolito D; Delle Marchette M; Paderno M; Adorni M; Jaconi M; Romualdi C; D'Incalci M; Siravegna G; Marchini S
    Clin Cancer Res; 2021 May; 27(9):2549-2559. PubMed ID: 33323403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients.
    Tsui DWY; Cheng ML; Shady M; Yang JL; Stephens D; Won H; Srinivasan P; Huberman K; Meng F; Jing X; Patel J; Hasan M; Johnson I; Gedvilaite E; Houck-Loomis B; Socci ND; Selcuklu SD; Seshan VE; Zhang H; Chakravarty D; Zehir A; Benayed R; Arcila M; Ladanyi M; Funt SA; Feldman DR; Li BT; Razavi P; Rosenberg J; Bajorin D; Iyer G; Abida W; Scher HI; Rathkopf D; Viale A; Berger MF; Solit DB
    Genome Med; 2021 May; 13(1):96. PubMed ID: 34059130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted and Shallow Whole-Genome Sequencing Identifies Therapeutic Opportunities in p53abn Endometrial Cancers.
    Jamieson A; Sobral de Barros J; Cochrane DR; Douglas JM; Shankar S; Lynch BJ; Leung S; Martin S; Senz J; Lum A; Drew Y; Gilks CB; Huntsman DG; McAlpine JN
    Clin Cancer Res; 2024 Jun; 30(11):2461-2474. PubMed ID: 38536067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The copy number and mutational landscape of recurrent ovarian high-grade serous carcinoma.
    Smith P; Bradley T; Gavarró LM; Goranova T; Ennis DP; Mirza HB; De Silva D; Piskorz AM; Sauer CM; Al-Khalidi S; Funingana IG; Reinius MAV; Giannone G; Lewsley LA; Stobo J; McQueen J; Bryson G; Eldridge M; ; Macintyre G; Markowetz F; Brenton JD; McNeish IA
    Nat Commun; 2023 Jul; 14(1):4387. PubMed ID: 37474499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating tumor DNA: a noninvasive biomarker for tracking ovarian cancer.
    Yang F; Tang J; Zhao Z; Zhao C; Xiang Y
    Reprod Biol Endocrinol; 2021 Dec; 19(1):178. PubMed ID: 34861867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New immune phenotypes for treatment response in high-grade serous ovarian carcinoma patients.
    Torkildsen CF; Austdal M; Jarmund AH; Kleinmanns K; Lamark EK; Nilsen EB; Stefansson I; Sande RK; Iversen AC; Thomsen LCV; Bjørge L
    Front Immunol; 2024; 15():1394497. PubMed ID: 38947323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sensitive circulating tumor DNA-based residual disease detection in epithelial ovarian cancer.
    Kallio HM; Savolainen K; Virtanen T; Ryyppö L; Selin H; Martikainen P; Staff S; Kivinummi K; Sipola J; Vuorinen J; Nikkola J; Nykter M; Auranen A; Annala M
    Life Sci Alliance; 2024 Jun; 7(6):. PubMed ID: 38580393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Network-Based Integration of GWAS and Gene Expression Identifies a HOX-Centric Network Associated with Serous Ovarian Cancer Risk.
    Kar SP; Tyrer JP; Li Q; Lawrenson K; Aben KK; Anton-Culver H; Antonenkova N; Chenevix-Trench G; ; ; Baker H; Bandera EV; Bean YT; Beckmann MW; Berchuck A; Bisogna M; Bjørge L; Bogdanova N; Brinton L; Brooks-Wilson A; Butzow R; Campbell I; Carty K; Chang-Claude J; Chen YA; Chen Z; Cook LS; Cramer D; Cunningham JM; Cybulski C; Dansonka-Mieszkowska A; Dennis J; Dicks E; Doherty JA; Dörk T; du Bois A; Dürst M; Eccles D; Easton DF; Edwards RP; Ekici AB; Fasching PA; Fridley BL; Gao YT; Gentry-Maharaj A; Giles GG; Glasspool R; Goode EL; Goodman MT; Grownwald J; Harrington P; Harter P; Hein A; Heitz F; Hildebrandt MA; Hillemanns P; Hogdall E; Hogdall CK; Hosono S; Iversen ES; Jakubowska A; Paul J; Jensen A; Ji BT; Karlan BY; Kjaer SK; Kelemen LE; Kellar M; Kelley J; Kiemeney LA; Krakstad C; Kupryjanczyk J; Lambrechts D; Lambrechts S; Le ND; Lee AW; Lele S; Leminen A; Lester J; Levine DA; Liang D; Lissowska J; Lu K; Lubinski J; Lundvall L; Massuger L; Matsuo K; McGuire V; McLaughlin JR; McNeish IA; Menon U; Modugno F; Moysich KB; Narod SA; Nedergaard L; Ness RB; Nevanlinna H; Odunsi K; Olson SH; Orlow I; Orsulic S; Weber RP; Pearce CL; Pejovic T; Pelttari LM; Permuth-Wey J; Phelan CM; Pike MC; Poole EM; Ramus SJ; Risch HA; Rosen B; Rossing MA; Rothstein JH; Rudolph A; Runnebaum IB; Rzepecka IK; Salvesen HB; Schildkraut JM; Schwaab I; Shu XO; Shvetsov YB; Siddiqui N; Sieh W; Song H; Southey MC; Sucheston-Campbell LE; Tangen IL; Teo SH; Terry KL; Thompson PJ; Timorek A; Tsai YY; Tworoger SS; van Altena AM; Van Nieuwenhuysen E; Vergote I; Vierkant RA; Wang-Gohrke S; Walsh C; Wentzensen N; Whittemore AS; Wicklund KG; Wilkens LR; Woo YL; Wu X; Wu A; Yang H; Zheng W; Ziogas A; Sellers TA; Monteiro AN; Freedman ML; Gayther SA; Pharoah PD
    Cancer Epidemiol Biomarkers Prev; 2015 Oct; 24(10):1574-84. PubMed ID: 26209509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liquid Biopsy in the Clinical Management of High-Grade Serous Epithelial Ovarian Cancer-Current Use and Future Opportunities.
    Paracchini L; D'Incalci M; Marchini S
    Cancers (Basel); 2021 May; 13(10):. PubMed ID: 34069200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-grade serous ovarian cancer: the clone wars.
    Salomon-Perzyński A; Salomon-Perzyńska M; Michalski B; Skrzypulec-Plinta V
    Arch Gynecol Obstet; 2017 Mar; 295(3):569-576. PubMed ID: 28154920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Copy number signatures and mutational processes in ovarian carcinoma.
    Macintyre G; Goranova TE; De Silva D; Ennis D; Piskorz AM; Eldridge M; Sie D; Lewsley LA; Hanif A; Wilson C; Dowson S; Glasspool RM; Lockley M; Brockbank E; Montes A; Walther A; Sundar S; Edmondson R; Hall GD; Clamp A; Gourley C; Hall M; Fotopoulou C; Gabra H; Paul J; Supernat A; Millan D; Hoyle A; Bryson G; Nourse C; Mincarelli L; Sanchez LN; Ylstra B; Jimenez-Linan M; Moore L; Hofmann O; Markowetz F; McNeish IA; Brenton JD
    Nat Genet; 2018 Sep; 50(9):1262-1270. PubMed ID: 30104763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ReMixT: clone-specific genomic structure estimation in cancer.
    McPherson AW; Roth A; Ha G; Chauve C; Steif A; de Souza CPE; Eirew P; Bouchard-Côté A; Aparicio S; Sahinalp SC; Shah SP
    Genome Biol; 2017 Jul; 18(1):140. PubMed ID: 28750660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vesicular-Bound HLA-G as a Predictive Marker for Disease Progression in Epithelial Ovarian Cancer.
    Schwich E; Rebmann V; Horn PA; Celik AA; Bade-Döding C; Kimmig R; Kasimir-Bauer S; Buderath P
    Cancers (Basel); 2019 Aug; 11(8):. PubMed ID: 31382533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker.
    Taylor MS; Wu C; Fridy PC; Zhang SJ; Senussi Y; Wolters JC; Cajuso T; Cheng WC; Heaps JD; Miller BD; Mori K; Cohen L; Jiang H; Molloy KR; Chait BT; Goggins MG; Bhan I; Franses JW; Yang X; Taplin ME; Wang X; Christiani DC; Johnson BE; Meyerson M; Uppaluri R; Egloff AM; Denault EN; Spring LM; Wang TL; Shih IM; Fairman JE; Jung E; Arora KS; Yilmaz OH; Cohen S; Sharova T; Chi G; Norden BL; Song Y; Nieman LT; Pappas L; Parikh AR; Strickland MR; Corcoran RB; Mustelin T; Eng G; Yilmaz ÖH; Matulonis UA; Chan AT; Skates SJ; Rueda BR; Drapkin R; Klempner SJ; Deshpande V; Ting DT; Rout MP; LaCava J; Walt DR; Burns KH
    Cancer Discov; 2023 Dec; 13(12):2532-2547. PubMed ID: 37698949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Use of Serial Circulating Tumor DNA to Detect Resistance Alterations in Progressive Metastatic Breast Cancer.
    Jacob S; Davis AA; Gerratana L; Velimirovic M; Shah AN; Wehbe F; Katam N; Zhang Q; Flaum L; Siziopikou KP; Platanias LC; Gradishar WJ; Behdad A; Bardia A; Cristofanilli M
    Clin Cancer Res; 2021 Mar; 27(5):1361-1370. PubMed ID: 33323406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study.
    Si H; Kuziora M; Quinn KJ; Helman E; Ye J; Liu F; Scheuring U; Peters S; Rizvi NA; Brohawn PZ; Ranade K; Higgs BW; Banks KC; Chand VK; Raja R
    Clin Cancer Res; 2021 Mar; 27(6):1631-1640. PubMed ID: 33355200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pan-cancer circulating tumor DNA detection in over 10,000 Chinese patients.
    Zhang Y; Yao Y; Xu Y; Li L; Gong Y; Zhang K; Zhang M; Guan Y; Chang L; Xia X; Li L; Jia S; Zeng Q
    Nat Commun; 2021 Jan; 12(1):11. PubMed ID: 33397889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concordance Between Tumor and Germline BRCA Status in High-Grade Ovarian Carcinoma Patients in the Phase III PAOLA-1/ENGOT-ov25 Trial.
    Callens C; Vaur D; Soubeyran I; Rouleau E; Just PA; Guillerm E; Golmard L; Goardon N; Sevenet N; Cabaret O; Harter P; Gonzalez-Martin A; Fujiwara K; Cecere SC; Colombo N; Marth C; Vergote I; Maenpaa J; Pujade-Lauraine E; Ray-Coquard I
    J Natl Cancer Inst; 2021 Jul; 113(7):917-923. PubMed ID: 33372675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in the Tumor Immune Microenvironment during Disease Progression in Patients with Ovarian Cancer.
    Westergaard MCW; Milne K; Pedersen M; Hasselager T; Olsen LR; Anglesio MS; Borch TH; Kennedy M; Briggs G; Ledoux S; Kreuzinger C; Decken IV; Donia M; Castillo-Tong DC; Nelson BH; Svane IM
    Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33352957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utility of Circulating Tumor DNA in Different Clinical Scenarios of Breast Cancer.
    Mesquita A; Costa JL; Schmitt F
    Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33339259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.